McCallum R W, Sowers J R, Hershman J M, Sturdevant R A
J Clin Endocrinol Metab. 1976 Jun;42(6):1148-52. doi: 10.1210/jcem-42-6-1148.
Serum prolactin concentrations increased approximately 6-fold after oral or intravenous administration of 10 mg of metoclopramide to adult men. Prolactin remained significantly elevated up to 9 h after oral metoclopramide and for at least 2 h after iv metoclopramide. Bethanechol did not increase serum prolactin, and atropine did not inhibit metoclopramide-induced prolactin elevation, suggesting that the cholinergic-like properties of metoclopramide were not responsible for the observed prolactin responses. Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. As a potent stimulus of prolactin release, metoclopramide may be useful in clinical investigation of hypothalamic-pituitary function.
成年男性口服或静脉注射10毫克胃复安后,血清催乳素浓度增加约6倍。口服胃复安后,催乳素在长达9小时内仍显著升高;静脉注射胃复安后,催乳素至少在2小时内显著升高。氨甲酰甲胆碱不会增加血清催乳素,阿托品也不会抑制胃复安引起的催乳素升高,这表明胃复安的拟胆碱能特性与观察到的催乳素反应无关。用500毫克左旋多巴预处理可抑制胃复安早期引起的催乳素升高,这与胃复安通过抑制多巴胺介导的下丘脑催乳素抑制因子分泌起作用的可能性一致。作为催乳素释放的有效刺激物,胃复安可能在下丘脑-垂体功能的临床研究中有用。